GSK (GSK) announced that the FDA has approved Exdensur as an add-on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in adult and pediatric patients aged 12 years and older.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK says FDA approves Exdensur as add-on maintenance treatment
- GSK announces marketing authorization of Exdensur in UK for added indication
- GSK’s New Study on Belantamab Mafodotin: A Potential Game-Changer for Multiple Myeloma Treatment
- GSK’s SPHERE Study Completes: A New Horizon for Pediatric HES Treatment
- GSK’s IPF Drug Study Terminated: Implications for Investors